1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
United States Army Medical Research and Development Command Broad Agency Announcement (USAMRDC BAA) is sponsored by Dept. of the Army -- USAMRAA. The USAMRDC BAA is a continuously open announcement soliciting extramural research and development ideas to benefit both military and civilian medical practice and knowledge.
Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
* **Contract Opportunity Type:** Special Notice (Updated) * **Updated Published Date:** Oct 03, 2022 08:18 am EDT * **Original Published Date:**Sep 29, 2022 01:37 pm EDT * **Updated Response Date:** Sep 30, 2027 11:59 pm EDT * **Original Response Date:**Sep 28, 2027 11:59 pm EDT * **Inactive Policy:**15 days after response date * **Updated Inactive Date:** * **Original Inactive Date:** * **Original Set Aside:** * **Product Service Code:** * **Place of Performance:** The USAMRDC’s mission is to provide solutions to medical problems of importance to the American Service Member at home and abroad, as well as to the general public at large.
The scope of this effort and the priorities attached to specific projects are influenced by changes in military and civilian medical science and technology (S&T), operational requirements, military threat assessments, and national defense strategies. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRDC.
General information on the USAMRDC can be obtained at https://mrdc. health. mil/.
This BAA is intended to solicit extramural research and development ideas using the authority provided by 10 USC 4001. The BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in FAR 6. 102(d)(2) and 35.
016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22. 315. In accordance with FAR 35.
016, projects funded under this BAA must be for basic and applied research to support scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution.
Research and development funded through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. This BAA utilizes competitive procedures in accordance with 10 USC 2302(2)(B) for the selection for award of S&T proposals/applications.
For the purposes of this BAA, S&T includes activities involving basic research, applied research, advanced technology development, and, under certain conditions, may include activities involving advanced component development and prototypes.
The selection process is highly competitive, and the quantity of meaningful submissions (both pre-proposals/pre-applications and full proposals/applications) received typically exceeds the number of awards that available funding can support.
This BAA provides a general description of USAMRDC’s research and development programs, including Research Areas of Interest, evaluation and selection criteria, pre-proposal/ pre-application and full proposal/application preparation instructions, and general administrative information.
Specific submission information and additional administrative requirements can be found in the document titled, “General Submission Instructions,” which is available on Grants. gov along with this BAA. The FY23-FY27 USAMRDC BAA is continuously open for a 5-year period, from October 1, 2022 through September 30, 2027, at 11:59 p.
m. Eastern Time. Submission of a pre-proposal/pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.
org/). Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period. If the USAMRDC is interested in receiving a full proposal/application, the Principal Investigator will be sent an invitation to submit via eBRAP.
A full proposal/application must be submitted through Grants. gov (http://www. grants.
gov/). Invited full proposals/applications can be submitted under this FY23-FY27 BAA through September 30, 2027. * BLDG 820 PBO 820 CHANDLER STREET * FORT DETRICK , MD 21702-5014 * **Nov 08, 2023 12:37 pm EST**Special Notice (Updated) * **Oct 03, 2022 08:18 am EDT**Special Notice (Updated) * **Sep 29, 2022 01:39 pm EDT**Special Notice (Updated) * **Sep 29, 2022 01:37 pm EDT**Special Notice (Original)
According to the current listing, eligibility includes: Research proposals/applications are sought from national, international, for-profit, non-profit, public, and private organizations. Confirm the full requirements in the official notice before applying.
Applications for United States Army Medical Research and Development Command Broad Agency Announcement (USAMRDC BAA) are due September 30, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
United States Army Medical Research and Development Command Broad Agency Announcement (USAMRDC BAA) is funded by Dept. of the Army -- USAMRAA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article